How to Choose a Regenerative Medicine Clinic

What “good” looks like

A good regenerative clinic starts with a diagnosis you can repeat, standard alternatives, and a product identity you can write down. For a tendon or an osteoarthritic knee, that usually means examination, indicated imaging, load-based care, and an honest sentence about what an injection can and cannot do. AAOS OrthoInfo treats PRP as a possible adjunct with mixed evidence—not as guaranteed cartilage or tendon regrowth.

Good clinics separate lawful products from slogans. They can say whether the offering is autologous PRP, a qualifying 361 HCT/P, an FDA-approved cellular product for a labeled indication, or an investigational 351 biologic under an IND. FDA consumer pages state that marketed stem-cell, exosome, cord, amniotic, and fat-derived products are generally unapproved for orthopedic pain, neurologic disease, and aging. A good clinic does not talk around that paragraph.

Procedure quality looks ordinary and slightly boring: sterile single-use supplies, image guidance when the target requires it, a medication and anticoagulant review, a rehabilitation plan, and a named person for infection or flare. ISSCR’s patient guide asks whether the doctors specialize in your disease and whether you can get a second opinion. Those are features of medical care, not of a weekend tourism package.

Good care will also tell you when to stop and when to see a surgeon. Temporary pain relief is not joint replacement. A clinic that promises you will never need arthroplasty, or that one unnamed vial treats arthritis, neuropathy, and aging, is selling a catalog—not a plan.

Credentials and scope to verify

Confirm an active professional license and a specialty that matches the problem: orthopedics, sports medicine, physical medicine, interventional spine, or another clinician who actually manages that joint or tendon. Check the state medical board. Ask who evaluates, who prepares the product, who injects, and who is in the building if you hypotense or develop a fever that night.

Product credentials are separate from clinician credentials. Ask for the manufacturer, lot, source, and FDA status. Search FDA’s approved cellular and gene-therapy list if they claim approval. Registration of a tissue establishment is not a BLA. Clearance of a centrifuge is not approval of an arthritis indication. Autologous does not mean exempt. FDA warning letters show licensed settings can still market unlicensed biologics.

Verify imaging and infection control. Ultrasound or fluoroscopy should have a trained operator. Single-use needles, closed processing, and a hospital-transfer plan are ordinary procedure standards. CDC-style injection safety still applies in a cash suite. Shared vials and hotel-room harvests are disqualifying.

Scope includes what they will not inject. A sudden hot joint, a possible rupture, or a neurologic emergency belongs in urgent care, not a regenerative add-on day. ISSCR guidance wants a specialist in the disease. A longevity generalist selling cord tissue for Parkinson’s and knees in the same hour fails that test.

Questions to ask

1. What is my diagnosis, and what standard care have we not yet done?
2. What exact product, dose, and lot will you use?
3. Is this FDA-approved for this use, a claimed 361 HCT/P, or an IND study?
4. May I see the carton, package insert, or IND consent?
5. Will you use image guidance, and who interprets the images?
6. What infection, bleeding, and failure plan do you own after hours?
7. What outcome at three and six months would make us stop or refer to surgery?
8. What is the itemized cost, including imaging, rehab, and complication care?

Listen for numbers and names. “Our proprietary stem-cell protocol” is not an answer. “FDA registered” is not approval. “Everyone gets the same vial” is a red flag. AAOS language on PRP is cautious and prep-specific; a clinic that treats PRP, BMAC, and cord tissue as synonyms is not reading the same documents.

Ask whether you can take the records to an independent orthopedic or sports-medicine second opinion. ISSCR tells patients not to be rushed. A same-day multi-injection package before you can think is a sales process.

Red flags

• Guaranteed cartilage regrowth, age reversal, or a cure for unrelated diseases.
• One unnamed product for arthritis, neuropathy, autism, and sexual function.
• Cash stem-cell tourism with no U.S. follow-up owner.
• Registration, centrifuge clearance, or a trial listing sold as approval.
• No imaging, no exam, and pressure to buy before you leave.
• Refusal to name manufacturer, lot, sterile process, or FDA pathway.
• Advice to skip indicated physical therapy or indicated joint replacement.
• Pay-to-participate “research” without an IND, eligibility, or a medical monitor.

Tourism is a special case of the same pattern: lower price, weaker accountability, and a product that would not be licensed at home. Infection and financial loss travel with you. FDA alerts exist because people were harmed. Walk if the brochure needs a passport more than it needs a diagnosis.

Cost, time, and logistics

Get an itemized quote: consult, imaging, harvest if any, product, facility, guidance, rehabilitation, follow-up, and who pays if you need an ER visit. PRP series and marrow harvests are often cash. Insurance may cover the evaluation and PT even when it will not cover a biologic. A bundled “stem-cell day” that hides the vial cost is not a transparent plan.

Time includes rehab. Tendon and knee OA programs take months of loading. An injection week without PT is incomplete. Travel adds jet lag, lost follow-up, and a hard time returning for a septic joint. If you cannot stay for complication care, do not buy the procedure.

Logistics also include second opinions. Take the product name to an independent clinician before you fly. Check FDA’s approved-product list and consumer alerts yourself. ISSCR’s handbook is written for that homework. A clinic that discourages outside review is selecting customers, not protecting patients.

Set a stop rule. One well-defined adjunct after a real diagnosis and a loading plan is enough to judge. Do not stack cord, fat, and exosome packages because the first shot felt incomplete. Keep ordinary orthopedic and primary care. License, FDA status, imaging, and a named diagnosis are the checklist. Cash stem-cell tourism is what you are trying not to buy.